2015运城冠心病诊疗进展_杨伟宪PPT课件.ppt

Title: PLATO研究: Primary Efficacy Endpoint (Composite of 心血管死亡, 心梗, or 卒中) Key Points: 替格瑞洛 significantly reduces the combined risk of 心血管死亡, 心梗, or 卒中 vs 氯吡格雷 in patients with ACS The absolute risk reduction of 替格瑞洛 over 氯吡格雷 starts early and continues to build over the full 1-year treatment regimen 替格瑞洛 provided benefits in the critical early period of risk. Importantly, the benefits were consistent over time The Kaplan-Meier curves continued to diverge up to 12 months, demonstrating a benefit beyond the acute phase Additional Information: In the PLATO研究, 替格瑞洛 significantly decreased the rate of the combined endpoint of 心血管死亡, 心梗, and 卒中 in ACS patients with UA, NSTEMI, or STEMI who were medically or invasively managed1,2 The difference in treatments was driven by reduced risk of 心血管死亡 and 心梗, with 否 significant difference in the rate of 卒中3 In the first 30 days, an absolute risk reduction of 0.6% (P=0.045) was seen with 替格瑞洛 as compared to 氯吡格雷, with a 风险率 of 0.88 (95% CI, 0.77–1.00) Improvement in the absolute risk reduction continued over the full 12 months (ARR: 1.9%, P0.001) and was seen with 替格瑞洛 as compared to 氯吡格雷 (HR: 0.84 [95% CI, 0.77–0.92]) In the PLATO研究 trial, for every 54 ACS patients treated with 替格瑞洛 instead of 氯吡格雷 one atherothrombotic event (NNT=54) was prevented References: Wallentin L, Becker RC, Bujah A, et al. 替格瑞洛 versus 氯吡格雷 in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–1057. Supplement to: Wallentin L, Becker RC, Budaj A, et al. 替格瑞洛 versus 氯吡格雷 in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–1057. BRILIQUE: Summary of Product 特征s, 2010. Title: PLATO研究: Predefined Testing of Primary and Major Secondary Efficacy Endpoints Key Points: 替格瑞洛 significantly decreased the rate of the primary efficacy endpoint of 心血管死亡, 心梗, and 卒中 in ACS patients with UA, NSTEMI, or STEMI who were medically or invasively managed1,2 The difference in treatments was driven by reduced risk of 心血管死亡 and 心梗, wit